AbbVie Inc. [NYSE: ABBV] gained 0.75% or 1.13 points to close at $152.09 with a heavy trading volume of 6506406 shares. The company report on April 29, 2022 that RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis.
Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with RINVOQ versus 26% and 18.2% with placebo) at week 14 compared to placebo1.
RINVOQ demonstrated significant improvement in signs and symptoms of AS at week 141-4.
It opened the trading session at $151.27, the shares rose to $154.53 and dropped to $150.51, the range by which the price of stock traded the whole day. The daily chart for ABBV points out that the company has recorded 31.04% gains over the past six months. However, it is still -44.08% lower than its most recent low trading price.
If we look at the average trading volume of 7.84M shares, ABBV reached to a volume of 6506406 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $164.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Daiwa Securities have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on April 06, 2022, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise from $129 to $147, while UBS kept a Neutral rating on ABBV stock. On February 03, 2022, analysts increased their price target for ABBV shares from 117 to 122.
The Average True Range (ATR) for AbbVie Inc. is set at 5.02, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.76. The Price to Book ratio for the last quarter was 17.50, with the Price to Cash per share for the same quarter was set at 5.59. Price to Free Cash Flow for ABBV in the course of the last twelve months was 21.18 with Quick ratio for the last quarter at 0.70.
Trading performance analysis for ABBV stock
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.66. With this latest performance, ABBV shares dropped by -13.07% in over the last four-week period, additionally plugging by 31.04% over the last 6 months – not to mention a rise of 32.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 44.10, with the RSI for the last a single of trading hit 43.57, and the three-weeks RSI is set at 46.14 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 157.07, while it was recorded at 151.93 for the last single week of trading, and 130.87 for the last 200 days.
AbbVie Inc. [ABBV]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +35.14 and a Gross Margin at +69.49. AbbVie Inc.’s Net Margin is presently recorded at +20.41.
Return on Equity for this stock inclined to 80.52, with Return on Assets sitting at 7.72.
AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.80.
AbbVie Inc. [ABBV]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 2.13%.
An analysis of insider ownership at AbbVie Inc. [ABBV]
There are presently around $179,703 million, or 69.70% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 146,312,069, which is approximately 0.538% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 128,197,554 shares of the stock with an approximate value of $19.35 billion in ABBV stocks shares; and STATE STREET CORP, currently with $11.98 billion in ABBV stock with ownership of nearly 3.383% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,497 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 59,367,729 shares. Additionally, 1,299 investors decreased positions by around 50,706,123 shares, while 340 investors held positions by with 1,080,329,135 shares. The mentioned changes placed institutional holdings at 1,190,402,987 shares, according to the latest SEC report filing. ABBV stock had 285 new institutional investments in for a total of 4,691,754 shares, while 105 institutional investors sold positions of 3,797,066 shares during the same period.